Long‐acting beta2‐agonists versus anti‐leukotrienes as add‐on therapy to inhaled corticosteroids for chronic asthma
Information
- DOI:
- https://doi.org/10.1002/14651858.CD003137.pub3Copy DOI
- Database:
-
- Cochrane Database of Systematic Reviews
- Version published:
-
- 18 October 2006see what's new
- Type:
-
- Intervention
- Stage:
-
- Review
- Cochrane Editorial Group:
-
Cochrane Airways Group
- Copyright:
-
- Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Article metrics
Altmetric:
Cited by:
Authors
Contributions of authors
Francine M. Ducharme reviewed the protocol design, supervised the literature search, reviewed all citations, participated in the selection of trials, methodology assessment, and data extraction, corresponded with authors and/or the pharmaceutical companies to identify other relevant trials, verify methodology and data extraction and request additional information, analysed and interpreted results of the meta‐analysis, and took part in writing up the final review.
Toby Lasserson (Update 2006 & 2008): Assessed studies for inclusion/exclusion, extracted & entered data, revised Results section.
Christopher Cates edited the review, checked the methodology, and contributed to writing up the final review.
Felix Ram participated in the initial version of the review (2005): protocol design, identified and reviewed the full‐text publication of all citations of potential or potentially eligible RCTs, extracted the methodology and data, analysed and interpreted results of the meta‐analysis, and wrote the first draft of the review.
Sources of support
Internal sources
-
No sources of support supplied
External sources
-
Nederlands Astma Fonds, Netherlands.
-
Francine M. Ducharme, Canada.
-
NHS Research and Development, UK.
Declarations of interest
Francine M. Ducharme has received travel support for meeting attendance, research funds, fees for speaking and/or consulting fees from AstraZeneca (producer of Zafirlukast, formoterol, and budesonide), Merck Frosst Inc (producer of Montelukast), GlaxoSmithKline (producer of fluticasone, beclomethasone, salmeterol), and Novartis (producer of formoterol ). No conflict reported by Toby Lasserson or Christopher Cates.
Acknowledgements
We are indebted to Liz Arnold and Veronica Stewart from the Cochrane Airways Review Group editorial base for extensive ongoing support with identifying, retrieving and translating literature. Francine M. Ducharme was supported by a National Scientist Award from the Fonds de la Recherche en Santé du Québec. We acknowledge the contribution of Felix Ram to the first iteration of this review. We are indebted to the following individuals who replied to our request for confirmation of methodology and data extraction, and graciously provided additional data whenever possible: Karen Richardson and Inge Vestbo from GlaxoSmithKline, UK; Ian Naya from AstraZeneca, Sweden; Nitesh Shah and Graham Debney from AstraZeneca, England and Peter Polos and Steven Bird from Merck Frosst, USA.
Version history
| Published | Title | Stage | Authors | Version |
| 2014 Jan 24 | Addition to inhaled corticosteroids of long‐acting beta<sub>2</sub>‐agonists versus anti‐leukotrienes for chronic asthma | Review | Bhupendrasinh F Chauhan, Francine M Ducharme | |
| 2011 May 11 | Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma | Review | Francine M Ducharme, Toby J Lasserson, Christopher J Cates | |
| 2006 Oct 18 | Long‐acting beta2‐agonists versus anti‐leukotrienes as add‐on therapy to inhaled corticosteroids for chronic asthma | Review | Francine M Ducharme, Toby J Lasserson, Christopher J Cates | |
| 2005 Jan 24 | Long‐acting beta2‐agonists versus anti‐leukotrienes as add‐on therapy to inhaled corticosteroids for chronic asthma | Review | Felix S F Ram, Christopher J Cates, Francine Ducharme | |
| 2001 Jul 23 | Anti‐leukotrienes versus long‐acting beta2‐agonists as add‐on therapy to inhaled corticosteroids for chronic asthma | Protocol | Felix SF Ram, Francine M Ducharme | |
Differences between protocol and review
In the protocol published in April 2001, we had planned to examine the impact of the inhaled glucocorticoids (subgroups 3) and of baseline severity (subgroups 5) as sensitivity analyses but changed it to subgroup analyses because it enhanced the clarity of interpretation. The last subgroup analysis (6), not initially considered in 2001, was added to the list subsequently as recent data indicated that the number of inhaler devices to deliver LABA + ICS might be an important effect modifier (Nelson 2003).
